IMTX

$9.83

Post-MarketAs of Mar 17, 8:00 PM UTC

Immatics N.V., a clinical-stage biopharmaceutical company, focuses on the research and development of potential T cell redirecting immunotherapies for the treatment of cancer in the United States.

OverviewIntradayAnalysisPROIntelligencePROAsk AIPRO

Historical Price

Price (Line)
Synthesizing Whystock Narrative...
Loading Financials...

Peer Comparison

JNJUNHPFE

Whystock Valuation Model

Calculated using a trailing P/E relative model adjusted by sector ROE and historical growth.
Current Price$9.83
Potential Upside
5%
Whystock Fair Value$10.32
Price
UndervaluedFair ValueOvervalued

Fundamentals

SectorHealthcare
IndustryBiotechnology

Immatics N.V., a clinical-stage biopharmaceutical company, focuses on the research and development of potential T cell redirecting immunotherapies for the treatment of cancer in the United States. The company is developing targeted immunotherapies wi...

Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$1.32B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
1.35
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROIC
Average efficiency. Growth may require heavy reinvestment.
-37.10%
Quick Ratio
Pristine liquidity. Sufficient cash to cover all near-term obligations.
11.07

Recent News

Simply Wall St.
Mar 15, 2026

Immatics Phase 3 Progress Sharpens View On Anzu Cel Launch Upside

Immatics (NasdaqCM:IMTX) reported strong enrollment in its Phase 3 SUPRAME trial for anzu-cel (IMA203), its lead cancer immunotherapy candidate. The company has set timelines for the final analysis of the trial and is targeting a future product launch following completion. This update outlines the next key clinical and regulatory steps for Immatics' late stage oncology pipeline. Immatics focuses on T cell based cancer therapies, with anzu-cel at the center of its late stage efforts. For you...

BEARISH
Negative press. News cycle fixated on risk factors or misses.
Insider Monkey
Mar 13, 2026

Immatics N.V. (IMTX) Seeing Strong Enrollment in a Key Phase 3 Trial of Drug Candidate

Immatics N.V. (NASDAQ:IMTX) is among the best German stocks to buy according to analysts. On March 5, Immatics N.V. (NASDAQ:IMTX) reported its financial results for the year ended December 31. It also provided updates on its business. On the financial part, the company reported revenue of $56.8 million, compared to revenue of $183.1 million in […]

BULLISH
Positive press. Headlines skewed toward growth and analyst upgrades.
Associated Press Finance
Mar 5, 2026

Immatics: Q4 Earnings Snapshot

TUBINGEN, Germany (AP) — Immatics N.V. (IMTX) on Thursday reported a loss of $41.6 million in its fourth quarter. The Tubingen, Germany-based company said it had a loss of 34 cents per share. The company posted revenue of $23 million in the period.

BEARISH
Negative press. News cycle fixated on risk factors or misses.
Zacks
Feb 26, 2026

Mirum Pharmaceuticals, Inc. (MIRM) Reports Q4 Loss, Tops Revenue Estimates

Mirum Pharmaceuticals (MIRM) delivered earnings and revenue surprises of -650.00% and +5.42%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?

BULLISH
Positive press. Headlines skewed toward growth and analyst upgrades.
Simply Wall St.
Jan 15, 2026

Institutional investors own a significant stake of 38% in Immatics N.V. (NASDAQ:IMTX)

Key Insights Significantly high institutional ownership implies Immatics' stock price is sensitive to their trading...

BULLISH
Positive press. Headlines skewed toward growth and analyst upgrades.